160 related articles for article (PubMed ID: 37413715)
1. Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: A meta-analysis.
Yang J; He Z; Li M; Hong T; Ouyang T
J Stroke Cerebrovasc Dis; 2023 Aug; 32(8):107243. PubMed ID: 37413715
[TBL] [Abstract][Full Text] [Related]
2. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.
Carney BJ; Uhlmann EJ; Puligandla M; Mantia C; Weber GM; Neuberg DS; Zwicker JI
J Thromb Haemost; 2019 Jan; 17(1):72-76. PubMed ID: 30450803
[TBL] [Abstract][Full Text] [Related]
3. Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review.
Iyengar V; Agrawal S; Chiasakul T; Tehranchi K; Mcnichol M; Carney BJ; Leader A; Zwicker JI; Patell R
J Thromb Haemost; 2024 Feb; 22(2):423-429. PubMed ID: 37866517
[TBL] [Abstract][Full Text] [Related]
4. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
[TBL] [Abstract][Full Text] [Related]
5. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
Swartz AW; Drappatz J
Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases.
Abdelmessih E; Ahuja T; Wo S; Sango A; Papadopoulos J; Green D; Xiang E
J Thromb Thrombolysis; 2024 Mar; 57(3):418-427. PubMed ID: 38281232
[TBL] [Abstract][Full Text] [Related]
8. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases.
Leader A; Hamulyák EN; Carney BJ; Avrahami M; Knip JJ; Rozenblatt S; Beenen LFM; Yust-Katz S; Icht O; Coppens M; Raanani P; Middeldorp S; Büller HR; Zwicker JI; Spectre G
Blood Adv; 2020 Dec; 4(24):6291-6297. PubMed ID: 33351124
[TBL] [Abstract][Full Text] [Related]
9. Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis.
Rojas-Hernandez CM; Oo TH; García-Perdomo HA
J Thromb Thrombolysis; 2017 Feb; 43(2):233-240. PubMed ID: 27704333
[TBL] [Abstract][Full Text] [Related]
10. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis.
Giustozzi M; Proietti G; Becattini C; Roila F; Agnelli G; Mandalà M
Blood Adv; 2022 Aug; 6(16):4873-4883. PubMed ID: 35772127
[TBL] [Abstract][Full Text] [Related]
11. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
[TBL] [Abstract][Full Text] [Related]
12. Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?
Jo J; Donahue J; Sarai G; Petroni G; Schiff D
Neuro Oncol; 2022 Mar; 24(3):455-464. PubMed ID: 34383073
[TBL] [Abstract][Full Text] [Related]
13. The risk of intracranial hemorrhage in glioma patients receiving anticoagulant treatment for venous thromboembolism: a bayesian network meta-analysis.
Huo H; Shen S; Yang Y; Zhang H; Wu S; Bi T; Li Y
J Thromb Thrombolysis; 2023 Aug; 56(2):333-341. PubMed ID: 37341895
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials.
Elbadawi A; Shnoda M; Mahmoud K; Elgendy IY
Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):380-388. PubMed ID: 32556105
[TBL] [Abstract][Full Text] [Related]
15. Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.
Diaz M; Jo J
Curr Oncol Rep; 2022 Apr; 24(4):493-500. PubMed ID: 35179708
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials.
Brunetti ND; Tricarico L; Correale M; De Gennaro L; Santoro F; Ieva R; Di Biase M
J Thromb Thrombolysis; 2020 Aug; 50(2):305-310. PubMed ID: 31654194
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis.
Dong Y; Wang Y; Ma RL; Liu M; Gao JZ; Su WY; Yan L; Sun JJ
J Thromb Thrombolysis; 2019 Oct; 48(3):400-412. PubMed ID: 31062143
[TBL] [Abstract][Full Text] [Related]
19. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
[TBL] [Abstract][Full Text] [Related]
20. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
